Isturisa
Isturisa ingredients
| Active ingredient | Strength |
|---|---|
| Osilodrostat Phosphate | 1 mg/1, 5 mg/1 |
What Isturisa is used for
The FDA lists the approved uses on the official label (below). In the EU, osilodrostat is approved as Isturisa for:
Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Isturisa
- Generic name
- Osilodrostat
- Made by
- Recordati Rare Diseases, Inc.
- Forms
- Tablet, Coated
- Given
- Oral
- Drug class
- Cortisol Synthesis Inhibitor
- FDA approval
- New drug application (NDA) NDA212801
- On the US market since
- 2020
Official information
- Isturisa prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Osilodrostat)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Isturisa?
Isturisa (Osilodrostat) is a specialist medicine made by Recordati Rare Diseases, Inc., approved by the US FDA.
What are the ingredients of Isturisa?
Isturisa contains Osilodrostat Phosphate (1 mg/1, 5 mg/1).
Is Isturisa approved in Europe?
The same active substance is approved in the EU as Isturisa.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA